Freedom of information (FOI) releases from OUH

This is a disclosure log of Oxford University Hospitals NHS Foundation Trust's responses to freedom of information (FOI) or environmental information regulations (EIR) requests that might be of wider public interest.

If you can't find the information you're looking for, you can make a new FOI request.

Filters

Clear filters

  • Keywords filters

  • Year filters

  • Month filters

25 disclosures

  1. New patient starts by month for certain breast cancer medicines

    Dear Oxford Universtiy Hospitals Please can you kindly confirm in writing:

    1. The number of new patient initiations per month with trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane [NICE TA458] – covering Sep 24 to Jan 2026 (inclusive)

    2. The number of new patient initiations with tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies [NICE TA786], by month, between Sep 24 and Jan 26

    Published: 18 March 2026

  2. Patient Information Leaflet Management

    Dear Freedom of Information Officer, I am writing to make a request under the Freedom of Information Act 2000. Please provide the following information about the management of patient information leaflets:

    1.OPERATIONAL RESPONSIBILITY The job title(s) of the person(s) or team responsible for the development, production, approval, and management of patient information leaflets (including printed and digital materials).

    2. DOCUMENT VOLUME AND PRODUCTION - The approximate number of patient information leaflets currently maintained by the Trust - The software or system(s) used to produce and manage these leaflets (e.g., Microsoft Word, desktop publishing software, dedicated patient information management systems)

    3. REPORTING STRUCTURE The job title of the senior manager to whom the person(s)/team(s) in question 1 directly report.

    4. BOARD-LEVEL ACCOUNTABILITY The job title of the Board-level executive with overall accountability for patient information materials.

    5. GOVERNANCE FRAMEWORK If the Trust has a formal policy or governance document covering patient information leaflets, please provide: - The document title and version number - The job title of the Board-level signatory or accountable executive named in that document - OR a copy of the policy itself if more convenient Please note: I do not require personal data such as names or contact details – job titles and reporting structures are sufficient. If any part of this request is likely to exceed the cost limit under Section 12 of the Act, please advise how the request could be refined. I would prefer to receive this information in electronic format. I look forward to your response within 20 working days as required by the Act.

    Published: 18 March 2026

  3. Monthly patient initiations for Camzyos (mavacamten)

    1. Please provide the monthly number of patients initiated onto the medication Camzyos (mavacamten) within your Trust from January 2025 to the most recent month for which data is available. I would like the data presented in a simple table format, for example: • January 2025: [Number] • February 2025: [Number] • (And so on...)

    2. Can you also provide the cumulative 2025 annual Camzyos ( mavacamten) patient initiation number This request has been designed to be as clear and manageable as possible. If any of the requested information is not readily available under your Freedom of Information obligations, please provide what is available with as much granularity as possible rather than declining the request in full.

    Published: 18 March 2026

  4. Use of SuperScript IV in AML NPM1 MRD testing

    Dear Freedom of Information Team, I am writing to make a request for information under the Freedom of Information Act 2000. This request concerns the use of Invitrogen SuperScript IV Reverse Transcriptase, a molecular biology reagent manufactured by Thermo Fisher Scientific, within acute myeloid leukaemia (AML) NPM1 (nucleophosmin 1) minimal residual disease (MRD) molecular testing pathways. Please provide the following information for the period 1 January 2018 to 31 December 2024. 1. Use of SuperScript IV Please confirm whether your Trust, or any laboratory operated by or on behalf of your Trust, used (Invitrogen) SuperScript IV Reverse Transcriptase (Thermo Fisher Scientific) as part of any AML NPM1 MRD testing undertaken for clinical decision-making during the above period. Please answer yes or no. 2. If yes If the answer to question 1 is yes, please provide: a) The years during which SuperScript IV was used in AML NPM1 MRD testing; b) Whether the relevant MRD assay was UKAS (United Kingdom Accreditation Service) accredited at the time of clinical use; c) Whether SuperScript IV was treated as Research Use Only (RUO) or otherwise subject to any diagnostic limitation or manufacturer warning; d) Whether any validation, governance approval, or risk assessment was undertaken specifically in relation to its use within AML NPM1 MRD testing (a high-level confirmation is sufficient). 3. Concerns or review Please confirm whether your Trust (including any relevant laboratory, pathology directorate, or governance function) identified, received, or was notified of any concerns, reviews, or discussions (including by email, meeting note, or internal memorandum) relating to the suitability, reliability, or governance of SuperScript IV (Thermo Fisher Scientific) for use in AML NPM1 MRD testing during the same period. If so, please provide the year or years in which such concerns arose and a high-level description of the action taken. This request does not seek personal data or information about individual patients or staff. Aggregate information and high-level confirmations are sufficient. If any part of this request is considered likely to exceed the appropriate cost limit, please advise how it may be refined before refusal, in accordance with Freedom of Information Act guidance.

    Published: 18 March 2026

  5. Expenditure on maternity and neonatal services

    Dear Freedom of Information Team, I am writing to request the following information under the Freedom of Information Act 2000. Please provide:

    1.Total annual expenditure on maternity services for each of the last five complete financial years (2020/21 to 2024/25, or most recent available). For each year, please confirm whether the figures represent: a) direct service‑line costs; b) allocated overheads; c) both of the above.

    2.Total annual expenditure on neonatal services for each of the last five complete financial years. For each year, please confirm whether the figures represent: a) direct service‑line costs; b) allocated overheads; c) both of the above.

    If available, please also provide any accompanying explanatory notes that clarify how service‑level expenditure is calculated within the Trust.

    Published: 16 March 2026

  6. Request for NHS trust data following new govt financial controls for the NHS

    Dear Sir/Madam, Freedom of Information Act Request: Impact of NHS financial requirements SECTION ONE: financial breakeven requirements From 2025-26, NHS England’s financial framework requires NHS trusts to meet a statutory breakeven duty. Where possible, trusts must avoid in-year deficits and recover prior deficits.

    Request (section one):

    1. Please provide the trust’s in-year deficit or surplus for 2024–25, and its estimated in-year deficit or surplus for 2025–26, 2026–27 and 2027–28. (Where the trust plans to break even, please confirm this. Where a deficit or surplus is projected, please state the estimated value.) SECTION TWO: efficiency, productivity and cost-reduction requirements NHS England has set mandatory efficiency measures, including: reducing organisational cost base by at least 1%; delivering around 4% productivity improvement; reducing corporate service spending to pre-pandemic levels; and reducing reliance on temporary and agency staffing.

    Request (section two):

    2a. Workforce reductions and permanently deleted posts Please provide the total number of job cuts, redundancies or post reductions that the trust has identified, planned or already implemented as a result of its breakeven duty and associated financial planning. If possible, please provide this information by financial year: 2025–26, 2026–27 and 2027–28. This should include job cuts or redundancies, and posts that have already been permanently deleted whether or not this resulted in redundancy. Where possible, and within statutory cost limits, please break this information down by staff group, for example: clinical staff, non-clinical staff, corporate / administrative staff Please express figures in full-time equivalent (FTE). Where only headcount figures are held, please provide these instead and indicate this.

    2b. Method of workforce reduction and post deletion Where possible, please provide a breakdown of how the workforce reductions and permanent post deletions described in section 2a are being or will be achieved, for example through: compulsory redundancies, voluntary redundancies, non-renewal of fixed-term contracts, natural wastage, vacancy controls or recruitment freezes. Where data is held, please break this information down by staff group (clinical/non-clinical/corporate, or equivalent categories used by the trust) and by financial year (2025–26, 2026–27, 2027–28).

    SECTION THREE: planned service reductions Breakeven planning may involve changes to service delivery, including reductions, reconfiguration or cessation of services. Request (section three): 3. Please outline any services, departments or functions that the trust has identified for reduction, reconfiguration or closure as part of its breakeven duty and medium-term financial plan, and indicate in which financial year(s) these changes are planned (2025–26, 2026–27 and/or 2027–28).

    Published: 16 March 2026

  7. Procurement Data

    Please provide the following information. 1. Please provide the record from the organisation's Contract Register or equivalent procurement log entry pertaining to the current contract for the Endpoint Detection and Response (EDR) solution (Include Supplier, Product Name, Start Date, Expiry Date, Annual spend 2025/2026 [£], Additional notes [including any framework used])  DEFINITION: The practice of securing organisational assets such as laptops, desktops, mobile phones, and servers against malicious activity. It encompasses tools and strategies designed to detect, prevent, and respond to threats directly on the device itself.

    2. Please provide the following information for the current maintenance and licensing agreement for the primary Perimeter Firewall/Intrusion Prevention System (IPS) solution (Include Supplier, Product Name, Start Date, Expiry Date, Annual spend 2025/2026 [£], Additional notes [including any framework used])  DEFINITION: The processes and technologies used to protect the boundaries (the perimeter) of an organisation's internal network from unauthorised external access. It involves monitoring and controlling incoming and outgoing network traffic.

    3. Please provide the following information for the service agreement covering the Cloud Security Posture Management (CSPM) platform or equivalent third-party cloud security monitoring too (Include Supplier, Product Name, Start Date, Expiry Date, Annual spend 2025/2026 [£], Additional notes [including any framework used])  DEFINITION: The set of security measures designed to protect data, applications, and infrastructure running in cloud environments (e.g., AWS, Azure, GCP). It also includes securing internally and externally facing applications themselves (application security).

    4. Please provide the following information for the service agreement covering your Identity & Access Management (IAM) software (Include Supplier, Product Name, Start Date, Expiry Date, Annual spend 2025/2026 [£], Additional notes [including any framework used])  DEFINITION: A framework of policies and technologies that ensures the right users have the appropriate access to the right resources at the right time. It involves managing digital identities, authentication (verifying identity), and authorisation (granting access).

    5. Please provide the record from the organisation's Contract Register or equivalent procurement log entry pertaining to the current contract for your current Managed Security / SOC Services (Include Supplier, Product Name, Start Date, Expiry Date, Annual spend 2025/2026 [£], Additional notes [including any framework used])  DEFINITION: The outsourcing of security monitoring and management to a third-party expert. A Security Operations Center (SOC) is a centralised function (internal or outsourced) responsible for continuous monitoring, threat analysis, and managing security incidents. 6. Please provide the record from the organisation's Contract Register or equivalent procurement log entry pertaining to the current contract for your current Vulnerability & Compliance Management service (Include Supplier, Product Name, Start Date, Expiry Date, Annual spend 2025/2026 [£], Additional notes [including any framework used])  DEFINITION: The continuous, cyclical practice of identifying, classifying, prioritising, remediating, and mitigating software weaknesses (vulnerabilities). Compliance Management ensures that security practices adhere to specific internal policies, regulatory requirements (like GDPR), and industry standards.

    Published: 16 March 2026

  8. Pregnancy and Baby Loss Framework People Policy for NHS Staff

    Dear FOI Team, Under the Freedom of Information Act 2000, I am writing to request the following information relating to NHS England’s National Pregnancy and Baby Loss People Policy Framework, published in March 2024. The framework applies to pregnant women and people who experience a pregnancy or baby loss before 24 weeks of pregnancy. This policy includes, but is not limited to: miscarriage, ectopic pregnancy, molar pregnancy, and termination of pregnancy.

    1. Does this NHS Trust apply the above-named framework regarding staff who have experienced a pregnancy or baby loss before 24 weeks of pregnancy into local trust policy?

    2. Are all staff who disclose a pregnancy loss entitled up to 10 days annual leave (pro-rata)? 3

    . What type of leave is given to those who disclose a pregnancy loss before 24 weeks of pregnancy (e.g. Sickness Leave, Compassionate Leave, Special Leave)?

    4. Are staff members who are partners of a woman or person who has experienced a pregnancy loss entitled up to 5 days leave (pro-rata)?

    5. Please provide any internal policy documents or guidance issued to staff regarding pregnancy and baby loss before 24 weeks of pregnancy, in an electronic format. A link to the framework is here: https://www.england.nhs.uk/publication/national-pregnancy-and-baby-loss-people-policy-framework/

    Published: 16 March 2026

  9. Annual cost of specialling

    1. What was the total cost of specialling at your Trust for the last financial year (or a recent 3 month period)? "Specialling" refers to 1-1 nursing observation and support, typically done by agency and/or bank nursing staff.

    Published: 9 March 2026

  10. Construction and refurbishment projects

    Hi, 1. Please can you provide me with a list of all current (financial year 2025/26), and planned (financial year 2026/27), construction and refurbishment projects.

    2. Additionally, the principal contractor awarded, and the sub-contractors awarded for the below sites by the Trust: a) Primary Hospitals John Radcliffe Hospital (Oxford) Churchill Hospital (Oxford) Nuffield Orthopaedic Centre (Oxford) Horton General Hospital (Banbury) b) Community Hospitals Thame Community Hospital Wallingford Community Hospital Wantage Community Hospital (plus Wantage Health Centre) Witney Community Hospital Also include any further satellite sites / acute hospital sites.

    Published: 2 March 2026